Vector Labs Ab04910-3.3 Anti-CTLA-4 [10D1 (Ipilimumab)], Mouse IgG2b, Fc Silent™, kappa (100 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: 10D1 (Ipilimumab)
Heavy Chain Modification: Fc Silent™
Synonyms: CTLA4; CD152; MDX-010; MDX-CTLA-4; MDX-CTLA4; YERVOY; BCD-145; nurulimab; BMS-734016; Cytotoxic T-lymphocyte protein 4; Cytotoxic T-lymphocyte-associated antigen 4
Amount: 100 μg
Application Codes Clone: Crystallography; WB; FACS; Therapeutic; ELISA; FC; Inhibition; SPR; in vitro; in vivo
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG1
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This is a reformatted mouse IgG2b Fc Silent™ antibody, based on the original mouse format, created for improved compatibility with existing reagents, assays and techniques.
Specificity Statement: This antibody binds CTLA-4. The antibody contacts the front β-sheet of CTLA-4 and intersects with the CTLA-4:Β7 ligand recognition surface. The antibody cross reacts with macaque CTLA-4. The antibody does not recognise CD28.
Application Notes: The specificity of the original format of the antibody was confirmed by ELISA analysis. The binding affinity of the IgG1 fragment to CTLA-4 was measured by surface plasmon resonance (Kd= 4 nM). This antibody bound to CTLA-4 expressed on the plasma membrane of T-cells and CTLA-4 expressed by normal human T cells by flow cytometry. The original format of the antibody stained positive control, human CTLA-4-expressing, 58αβCTLA4CD3zeta cells as well as positive control lymphocytes in human tonsil using an indirect immunoperoxidase method. The original format of the antibody reacted with macaque and human CTLA-4, but not with murine CTLA-4 by FACS analysis. The original format of the antibody efficiently inhibited CTLA-4-B7 interactions at low concentrations (1-10 μg/ml) by flow cytometry (US6984720B1). The original format of the antibody was shown to mediate antibody-dependent cell-mediated cytotoxicity (ADCC)-facilitated depletion of Treg cells in vitro (Romano et al., 2015; PMID: 25918390). The crystal structure of the Fab fragment of the antibody in complex with human CTLA-4 was determined. The Fab fragment of the antibody competed with hB7-1 for binding to hCTLA-4 in a bead-based FACS assay. The Fab fragment of the antibody detected human CTLA-4 by western blot analysis (Ramagopal et al., 2017; PMID: 28484017). The antibody received FDA approval for the treatment of metastatic melanoma in 2011.

Product Class:	Purified
Clone ID:	10D1 (Ipilimumab)
Heavy Chain Modification:	Fc Silent™
Synonyms:	CTLA4; CD152; MDX-010; MDX-CTLA-4; MDX-CTLA4; YERVOY; BCD-145; nurulimab; BMS-734016; Cytotoxic T-lymphocyte protein 4; Cytotoxic T-lymphocyte-associated antigen 4
Amount:	100 μg
Application Codes Clone:	Crystallography; WB; FACS; Therapeutic; ELISA; FC; Inhibition; SPR; in vitro; in vivo
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG1
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This is a reformatted mouse IgG2b Fc Silent™ antibody, based on the original mouse format, created for improved compatibility with existing reagents, assays and techniques.
Specificity Statement:	This antibody binds CTLA-4. The antibody contacts the front β-sheet of CTLA-4 and intersects with the CTLA-4:Β7 ligand recognition surface. The antibody cross reacts with macaque CTLA-4. The antibody does not recognise CD28.
Application Notes:	The specificity of the original format of the antibody was confirmed by ELISA analysis. The binding affinity of the IgG1 fragment to CTLA-4 was measured by surface plasmon resonance (Kd= 4 nM). This antibody bound to CTLA-4 expressed on the plasma membrane of T-cells and CTLA-4 expressed by normal human T cells by flow cytometry. The original format of the antibody stained positive control, human CTLA-4-expressing, 58αβCTLA4CD3zeta cells as well as positive control lymphocytes in human tonsil using an indirect immunoperoxidase method. The original format of the antibody reacted with macaque and human CTLA-4, but not with murine CTLA-4 by FACS analysis. The original format of the antibody efficiently inhibited CTLA-4-B7 interactions at low concentrations (1-10 μg/ml) by flow cytometry (US6984720B1). The original format of the antibody was shown to mediate antibody-dependent cell-mediated cytotoxicity (ADCC)-facilitated depletion of Treg cells in vitro (Romano et al., 2015; PMID: 25918390). The crystal structure of the Fab fragment of the antibody in complex with human CTLA-4 was determined. The Fab fragment of the antibody competed with hB7-1 for binding to hCTLA-4 in a bead-based FACS assay. The Fab fragment of the antibody detected human CTLA-4 by western blot analysis (Ramagopal et al., 2017; PMID: 28484017). The antibody received FDA approval for the treatment of metastatic melanoma in 2011.

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews